127 related articles for article (PubMed ID: 25470586)
21. Cost-effectiveness of interferon treatment for hepatitis C.
van Leeuwen DJ
JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
[No Abstract] [Full Text] [Related]
22. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
Gellad ZF; Reed SD; Muir AJ
Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of interferon treatment for hepatitis C.
Henley E
JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
[No Abstract] [Full Text] [Related]
24. [Economic evaluation of combined therapy in chronic hepatitis C].
Casado MA; Buti M; Fosbrook L; Esteban R
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
[No Abstract] [Full Text] [Related]
25. Effectiveness, costs weigh on HCV treatment decisions.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(14):1156-7. PubMed ID: 24973370
[No Abstract] [Full Text] [Related]
26. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
[No Abstract] [Full Text] [Related]
27. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
28. Telaprevir use in a chronic hepatitis C patient with hemophilia.
Guner R; Tufan ZK
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):248. PubMed ID: 24366457
[No Abstract] [Full Text] [Related]
29. [Hepatitis C. Saving the liver].
Paul A
MMW Fortschr Med; 1999 Nov; 141(46):16. PubMed ID: 10795138
[No Abstract] [Full Text] [Related]
30. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
[TBL] [Abstract][Full Text] [Related]
31. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
[TBL] [Abstract][Full Text] [Related]
32. [A report from the Chinese National Fourteenth Symposium on Viral Hepatitis and Liver Diseases].
Zhu HM; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):636-7. PubMed ID: 19719931
[No Abstract] [Full Text] [Related]
33. Antiviral treatment for cirrhosis due to hepatitis C: a review.
Somasundaram A; Venkataraman J
Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
[TBL] [Abstract][Full Text] [Related]
34. 'HepConomics': cost-effective, indeed, but how can we pay for it?
Athanasakis K; Petrakis I; Kyriopoulos J
J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
[No Abstract] [Full Text] [Related]
35. [Chronic hepatitis. 2: Treatment].
Blum HE; Moradpour D
Dtsch Med Wochenschr; 2001 Jul; 126(27):786-9; quiz 790-2. PubMed ID: 11486479
[No Abstract] [Full Text] [Related]
36. Resource use and cost of hepatitis C-related care.
Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
[TBL] [Abstract][Full Text] [Related]
37. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
Haj-Ali Saflo O; Hernández Guijo JM
Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
[TBL] [Abstract][Full Text] [Related]
38. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
Bublak R
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
[No Abstract] [Full Text] [Related]
39. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
40. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
Yoshida H; Tateishi R; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
